Brief: SynAct Pharma Q1 Adj. Loss per Share at EPS SEK 1.59
05/05/2023 06:12
May 5 (Reuters) - SynAct Pharma Q1 cash flow from operating activities SEK -30.472 million. * Q1 net income SEK -49.878 million * Q1 sales SEK 0 * Q1 operating expenses SEK 58.248 million * Q1 adjusted EPS SEK -1.59
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development